
Lilly's retatrutide beats Ozempic in a head-to-head diabetes study
Eli Lilly said its investigational drug retatrutide lowered blood sugar and cut weight more than Novo Nordisk's Ozempic in a large diabetes study. The so-called triple-G drug is one of the most watched obesity candidates. STAT reported the result in its biotech newsletter.
Read more at STAT →












